StockData

Liquidia vs Tenax Therapeutics

LQDA and TENX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LQDA and TENX compare

Liquidia is the larger company, worth 85 times as much as Tenax Therapeutics ($5.1B against $60.6M).

Liquidia scores higher on the StockData Score (10 against 6 for Tenax Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLQDATENX
Size and price
Market cap$5.1B$60.6M
Share price$57.41$1.62
Change, 1 year103%−76.8%
Change, 5 years1248%−99.9%
Beta (5Y)0.970.62
Employees21614
StockData Score
Total score10 (better)6
Valuation score01 (better)
Growth score2 (better)0
Performance score2 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S8.3×–
P/B–0.6×
P/FCF17.6×–
FCF yield5.7%–
Growth
Revenue growth (TTM)798%–
Revenue growth, 5Y average192%–
Profitability
Operating margin−15.6%–
Net margin−15.1%–
FCF margin46.8%–
Return on equity–−64.2%
Financial health
Debt / equity–0.00
Current ratio1.0214.01 (better)
Altman Z-score3.31 (better)−1.49
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions81.1%81.1%
Held by insiders19.5%4.8%
Insider net buying, 12 months−$227M$6.5M (better)
Short interest, % of float24.3%16.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.